<DOC>
	<DOCNO>NCT02799147</DOCNO>
	<brief_summary>Our group demonstrate low incidence acute chronic graft-versus-host disease ( GVHD ) post-transplantation cyclophosphamide ( PTCy ) haploidentical , unrelated related allogeneic stem cell transplantation ( SCT ) . Nonetheless majority graft , except 10/10 HLA-matched bone marrow , type prophylaxis require concomitant administration calcineurin inhibitorsÂ±MMF , delay immune reconstitution development graft-versus-leukemia ( GVL ) effect . So , despite reduction transplant-related mortality , use PTCy n't lead reduction relapse incidence . This particularly important relapse refractory acute leukemia patient , , despite effort intensify condition regimen , relapse SCT occur 50 % patient , long-term survival rarely exceed 10-20 % . In preclinical model haploidentical SCT substitution post-transplantation cyclophosphamide bendamustine , lead comparable GVHD control , significantly augment GVL effect . To test hypothesis improve outcome allogeneic SCT refractory acute leukemia patient initiate pilot trial high-dose post-transplantation bendamustine GVHD prophylaxis . The selection dos base previous dose-escalation study . No additional immunosuppression plan trial .</brief_summary>
	<brief_title>GVHD Prophylaxis With Post-transplantation Bendamustine Refractory Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Acute Disease</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Biphenotypic , Acute</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<mesh_term>Antineoplastic Agents , Alkylating</mesh_term>
	<criteria>Diagnosis : Acute Myeloblastic Leukemia Acute Lymphoblastic Leukemia MixedLineage Acute Leukemias Disease , refractory list one course induction chemotherapy immunotherapy More 5 % clonal blast bone marrow peripheral blood time inclusion Signed informed consent Matched relate , 810/10 HLAmatched unrelated haploidentical donor available . The HLA typing perform following genetic locus : HLAA , HLAB , HLACw , HLADRB1 , HLADQB1 . No second tumor No severe concurrent illness No previous autologous allogeneic stem cell transplantation Karnofsky index &lt; 70 % Moderate severe cardiac dysfunction , leave ventricular ejection fraction &lt; 50 % Moderate severe decrease pulmonary function , FEV1 &lt; 70 % DLCO &lt; 70 % predict Respiratory distress &gt; grade I Severe organ dysfunction : AST ALT &gt; 5 upper normal limit , bilirubin &gt; 1.5 upper normal limit , creatinine &gt; 1.5 upper normal limit Creatinine clearance &lt; 60 mL/min Uncontrolled bacterial fungal infection time enrollment , define CRP level &gt; 70 mg/L positive procalcitonin patient adequate empirical antibacterial antifungal therapy . Requirement vasopressor support time enrollment Pregnancy Somatic psychiatric disorder make patient unable sign inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Allogeneic Transplantation</keyword>
	<keyword>Hematopoietic Stem Cell Transplantation</keyword>
	<keyword>Leukemia , Acute Lymphoblastic</keyword>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>Mixed-Lineage Acute Leukemias</keyword>
	<keyword>Immune System Diseases</keyword>
	<keyword>Immunosuppressive Agents</keyword>
	<keyword>Myeloablative Agonists</keyword>
	<keyword>Busulfan</keyword>
	<keyword>Fludarabine</keyword>
	<keyword>Antineoplastic Agents , Alkylating</keyword>
	<keyword>Bendamustine Hydrochloride</keyword>
</DOC>